公开(公告)号：US20240350672A1

公开(公告)日：2024-10-24

申请号：US18617239

申请日：2024-03-26

申请人： BIOVERATIV THERAPEUTICS INC.

发明人： Tongyao LIU ,  Ekta Seth CHHABRA ,  Siyuan TAN

IPC分类号： A61K48/00 ,  A61K38/00 ,  A61P7/04 ,  C07K14/755 ,  C12N15/85

CPC分类号： A61K48/0058 ,  A61P7/04 ,  C07K14/755 ,  C12N15/85 ,  A61K38/00

摘要： The present disclosure provides codon optimized Factor VIII sequences, vectors, and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides.

公开(公告)号：US20240350619A1

公开(公告)日：2024-10-24

申请号：US18027132

申请日：2022-05-10

申请人： GUANGZHOU RIBOBIO CO., LTD. ,  ARGORNA PHARMACEUTICALS CO., LTD.

发明人： Bill Biliang ZHANG ,  Lin MA ,  Jian WEN ,  Hong ZHANG ,  Huiling ZHONG

IPC分类号： A61K39/215 ,  A61K39/00 ,  A61P31/14 ,  C07K14/005 ,  C12N7/00 ,  C12N15/11 ,  C12N15/85

CPC分类号： A61K39/215 ,  A61P31/14 ,  C07K14/005 ,  C12N7/00 ,  C12N15/11 ,  C12N15/85 ,  A61K2039/53 ,  A61K2039/55555 ,  A61K2039/70 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N2830/50

摘要： This disclosure provides vaccines and compositions based on SARS-COV-2 S protein, and specifically relates to recombinant SARS-COV-2 spike protein (Sprotein) and mRNA and DNA coding thereof. This disclosure also relates to recombinant plasmid comprising DNA sequence encoding recombinant S protein. This disclosure further relates to composition comprising the recombinant S protein and/or mRNA mentioned above, mRNA-carrier particle such as lipid nanoparticle (LNP), and composition such as a vaccine composition.

公开(公告)号：US20240349706A1

公开(公告)日：2024-10-24

申请号：US18305342

申请日：2023-04-22

申请人： INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

发明人： Eun Jig Lee ,  Daham Kim

IPC分类号： A01K67/027 ,  C07K14/72 ,  C12N15/85

CPC分类号： A01K67/0278 ,  C07K14/723 ,  C12N15/8509 ,  A01K2217/072 ,  A01K2217/203 ,  A01K2227/105 ,  A01K2267/0325 ,  C12N2015/8563 ,  C12N2800/30

摘要： The present invention relates to an autoimmune disease animal model and a method for preparing the same. The animal model of the present invention efficiently generates an autoantibody that causes autoimmune disease, by introducing an autoantigen-encoding gene through the Cre-LoxP system, which enables stable and continuous expression of the autoantigen at a desired time by treatment of Cre recombinase. Contrary to the conventional method that fails to effectively produce autoantibody due to leaky expression and immune tolerance, or requires repeated administration over several weeks, the present invention achieves sustainable expression of an effective amount of autoantigen by only one TAT-Cre recombinase treatment, thus may be utilized as an outstanding animal model reproducing various symptoms and molecular mechanisms of autoimmune diseases.

公开(公告)号：US20240344030A1

公开(公告)日：2024-10-17

申请号：US18292670

申请日：2022-07-28

申请人： Cartesian Therapeutics, Inc.

发明人： Yi Zhang ,  C. Andrew Stewart ,  Metin Kurtoglu ,  Sjaji Daniel ,  Murat V. Kalayoglu ,  Minhtran Ngo Casi

IPC分类号： C12N5/0775 ,  C07K14/54 ,  C07K14/715 ,  C07K16/28 ,  C12N15/85

CPC分类号： C12N5/0662 ,  C07K14/5434 ,  C07K14/7158 ,  C07K16/2809 ,  C07K16/2878 ,  C12N15/85 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/92 ,  C12N2800/107

摘要： Provided here are cells engineered for therapeutic purposes to express multiple proteins, including an anti-BCMA (B cell maturation antigen), anti-CD3 bispecific antibody. Also provided are new anti-BCMA, anti-CD3 bispecific antibodies with associated sequences. Further disclosed is a mesenchymal stem cell (MSC) comprising an exogenous mRNA encoding an anti-BCMA and anti-CD3 antibody, and an exogenous mRNA encoding a single-chain interleukin-12 (IL-12) fusion protein.

公开(公告)号：US20240343774A1

公开(公告)日：2024-10-17

申请号：US18758151

申请日：2024-06-28

申请人： Kansas State University Research Foundation

发明人： Raymond R.R. Rowland ,  Ana Stoian

IPC分类号： C07K14/705 ,  A01K67/027 ,  C12N15/85

CPC分类号： C07K14/705 ,  A01K67/027 ,  C12N15/85

摘要： The present disclosure provides compositions and methods for decreasing permissiveness to infection by PRRSV. The methods involve inserting peptides or oligopeptides into the CD163 SRCR domain 5 to disrupt the protein structure and thereby prevent PRRSV infection. The deletion of the exon 13 region of PSTII eliminates infection. The replacement of cysteine residues with alanines in SRCR5 as a means to disrupt disulfide bond formation. The final method is the deletion of, or amino acid substitution within the SRCR4-5 interdomain region.

公开(公告)号：US20240341291A1

公开(公告)日：2024-10-17

申请号：US18760465

申请日：2024-07-01

申请人： Regeneron Pharmaceuticals, Inc.

发明人： John MCWHIRTER ,  Cagan GURER ,  Lynn MACDONALD ,  Andrew J. MURPHY

IPC分类号： A01K67/0278 ,  C07K14/705 ,  C12N15/85 ,  G01N33/50

CPC分类号： A01K67/0278 ,  C07K14/70575 ,  C12N15/85 ,  G01N33/5088 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/07 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0325 ,  A01K2267/0381 ,  A01K2267/0387 ,  C07K2319/00 ,  G01N2500/10

摘要： Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized B-cell activating factor gene. Non-human animals and cells that express a human or humanized B-cell activating factor protein from an endogenous B-cell activating factor locus are described.

公开(公告)号：US12116401B2

公开(公告)日：2024-10-15

申请号：US17585981

申请日：2022-01-27

申请人： Bill & Melinda Gates Medicl Research Institute

发明人： Laura M. Walker

IPC分类号： C07K16/10 ,  A61K9/00 ,  A61K39/12 ,  A61P31/16 ,  C12N15/85 ,  A61K45/06

CPC分类号： C07K16/1027 ,  A61K9/0019 ,  A61K39/12 ,  A61P31/16 ,  C12N15/85 ,  A61K45/06 ,  C12N2760/18534

摘要： Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.

公开(公告)号：US20240327785A1

公开(公告)日：2024-10-03

申请号：US18543857

申请日：2023-12-18

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Lynn Macdonald ,  Sean Stevens ,  Cagan Gurer ,  Andrew J. Murphy ,  Karolina A. Meagher

IPC分类号： C12N5/0735 ,  A01K67/0275 ,  A01K67/0278 ,  C07K16/00 ,  C07K16/18 ,  C07K16/46 ,  C12N15/10 ,  C12N15/85

CPC分类号： C12N5/0606 ,  A01K67/0275 ,  A01K67/0278 ,  C07K16/00 ,  C07K16/18 ,  C07K16/461 ,  C07K16/462 ,  C12N15/10 ,  C12N15/8509 ,  A01K2207/15 ,  A01K2217/05 ,  A01K2217/052 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/02 ,  A01K2267/0381 ,  C07K2317/10 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/50 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/64

摘要： Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided.

公开(公告)号：US20240327496A1

公开(公告)日：2024-10-03

申请号：US18293889

申请日：2022-07-29

申请人： Pfizer Inc.

发明人： Kalpanie Ruwanmali Bandara ,  Kathryn Mary Beal ,  John Joseph Scarcelli ,  Lin Zhang

IPC分类号： C07K16/00 ,  C12N15/85

CPC分类号： C07K16/00 ,  C12N15/85 ,  C07K2317/14 ,  C07K2319/00 ,  C12N2800/30

摘要： Vectors and nucleic acid constructs for improved antibody production are provided. Also provided are methods of making and using the vectors and constructs.

公开(公告)号：US20240318148A1

公开(公告)日：2024-09-26

申请号：US18527746

申请日：2023-12-04

申请人： UNION HOSPITAL TONGJI MEDICAL COLLEGE HUST

发明人： Heng MEI ,  Yu HU ,  Zhaozhao CHEN

IPC分类号： C12N7/00 ,  C09B23/06 ,  C12N5/00 ,  C12N5/071 ,  C12N15/85

CPC分类号： C12N7/00 ,  C09B23/06 ,  C12N5/0037 ,  C12N5/0686 ,  C12N15/85 ,  C12N2500/34 ,  C12N2740/15043 ,  C12N2740/15051

摘要： The present disclosure belongs to lentiviral labeling technology, and in particular relates to a fluorescently labeled lentiviral vector, and a preparation method and use thereof. The preparation method of a fluorescently labeled lentiviral vector includes: preparation of N3-LVs: subjecting a 293T cell and an azido sugar to co-incubation, such that a cell membrane system is azidated through sugar metabolism to obtain an N3-293T cell capable of expressing an azido group on an envelope surface, and subjecting the N3-293T cell and a plasmid packaging system to co-transfection to form a lentiviral vector N3-LVs; and preparation of Cy5-LVs: mixing the N3-LVs with a sufficient amount of an azide dibenzocyclooctyne-cyanine 5 (DBCO-Cy5) to allow co-incubation, removing excess DBCO-Cy5, and collecting a virus concentrate to obtain a fluorescently labeled lentiviral vector Cy5-LVs. In the present disclosure, a simple and easy lentiviral fluorescent labeling technology is provided by covalently modifying fluorescein on an envelope surface of a lentivirus based on bioorthogonal click chemistry with a low cost.